Login / Signup

The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants.

Katrina Tatton-BrownAnna ZachariouChey LovedayAnthony RenwickShazia MahamdallieLise AksglaedeDiana BaralleDaniela Q C M Barge-SchaapveldMoira BlythMieke BoumaJeroen BreckpotBeau CrabbTabib DabirValerie Cormier-DaireChristine FauthRichard FisherBlanca GenerDavid GoudieTessa HomfrayMatthew HunterAgnete JorgensenSarina G KantCathy Kirally-BorriDavid KoolenAjith KumarAnatalia LabilloyMelissa LeesCarlo MarcelisCatherine MercerCyril MignotKathryn MillerKatherine NeasRuth Newbury-EcobDaniela T PilzRenata PosmykCarlos PradaKeri RamseyLinda M RandolphAngelo SelicorniDeborah ShearsMohnish SuriI Karen TemplePeter D TurnpennyLionel Van MaldergemVinod VargheseHermine E Veenstra-KnolNaomi YachelevichLaura Yatesnull nullnull nullNazneen Rahman
Published in: Wellcome open research (2018)
Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), also known as the DNMT3A-overgrowth syndrome, is an overgrowth intellectual disability syndrome first described in 2014 with a report of 13 individuals with constitutive heterozygous DNMT3A variants. Here we have undertaken a detailed clinical study of 55 individuals with de novoDNMT3A variants, including the 13 previously reported individuals. An intellectual disability and overgrowth were reported in >80% of individuals with TBRS and were designated major clinical associations. Additional frequent clinical associations (reported in 20-80% individuals) included an evolving facial appearance with low-set, heavy, horizontal eyebrows and prominent upper central incisors; joint hypermobility (74%); obesity (weight ³2SD, 67%); hypotonia (54%); behavioural/psychiatric issues (most frequently autistic spectrum disorder, 51%); kyphoscoliosis (33%) and afebrile seizures (22%). One individual was diagnosed with acute myeloid leukaemia in teenage years. Based upon the results from this study, we present our current management for individuals with TBRS.
Keyphrases